Pfizer Inc. (NYSE:PFE) Shares Acquired by Stockman Wealth Management Inc.

Stockman Wealth Management Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 23.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 355,871 shares of the biopharmaceutical company's stock after acquiring an additional 66,496 shares during the quarter. Stockman Wealth Management Inc.'s holdings in Pfizer were worth $9,018,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its stake in Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after acquiring an additional 2,285,276 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Pfizer by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock worth $3,190,131,000 after purchasing an additional 2,923,537 shares in the last quarter. Norges Bank acquired a new position in shares of Pfizer in the fourth quarter worth $2,328,986,000. Finally, Massachusetts Financial Services Co. MA raised its stake in Pfizer by 7.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after purchasing an additional 5,350,381 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Performance

NYSE PFE traded down $0.14 during trading hours on Monday, hitting $24.40. The company had a trading volume of 35,078,445 shares, compared to its average volume of 41,184,640. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The firm has a market cap of $138.71 billion, a P/E ratio of 17.30, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $23.06 and a 200-day simple moving average of $24.95.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.82 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.05%. Pfizer's payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.